Welcome to our dedicated page for Sana Biotechnology SEC filings (Ticker: SANA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sana Biotechnology, Inc. filings document the regulatory record for a public biotechnology company developing engineered-cell medicines. Recent 8-K reports disclose operating results, corporate presentations, program updates for UP421, SC451, and SG293, at-the-market common stock sales arrangements, executive appointments, and board-class governance matters.
Proxy materials describe annual meeting voting items, director elections, board structure, executive compensation, and stockholder governance procedures. The company’s filings also capture material agreements, capital-structure disclosures, Regulation FD presentations, and other event reports tied to its cell-therapy pipeline and public-company obligations.
Sana Biotechnology reported Q3 2025 results, highlighting lower operating expenses and a narrower loss. Total operating expenses were $43.5 million, down from $61.8 million a year ago, driven by research and development of $30.1 million and general and administrative of $10.3 million. Net loss was $42.2 million (basic and diluted net loss per share $0.16), improving from $59.9 million in Q3 2024.
Cash, cash equivalents, and marketable securities totaled $153.1 million as of September 30, 2025. The company completed an August underwritten offering for net proceeds of approximately $80.6 million and sold 7.3 million shares under an ATM for $28.6 million in Q3. Management states existing liquidity, together with these proceeds, will fund planned operations for at least one year from the filing. For the first nine months, operating cash outflow was $111.2 million; results include a non-cash impairment of $44.6 million recognized in Q2 tied to facilities in Bothell and Seattle. Stockholders’ equity was $195.3 million. Shares outstanding were 266,366,120 as of October 29, 2025.
Sana Biotechnology furnished a press release announcing financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.
The information was furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities or automatically incorporated by reference.
Insider acquisition recorded for Sana Biotechnology (SANA). A Form 4 filed for director Hans Edgar Bishop shows an acquisition on 10/06/2025 of 5,628 shares via fully vested restricted stock units (RSUs) issued at $0.00 as part of compensation. Following the transaction, the reporting person beneficially owns 5,834,583 shares in total. The filing was signed by an attorney-in-fact on 10/07/2025. The entry is coded as a non-derivative acquisition and the explanation confirms these were fully vested RSUs.
Sana Biotechnology, Inc. reported a planned leadership transition in its top legal role. Executive Vice President, General Counsel, and Corporate Secretary Bernard J. Cassidy intends to retire, with his retirement expected to be effective on October 20, 2025, immediately before his successor starts work. After retiring from his executive positions, he is expected to continue providing transition-related services.
The company states that Mr. Cassidy’s retirement is voluntary, for personal reasons, and not due to any disagreement about its operations, policies, or practices. Sana has entered into an offer letter with Aaron M. Grossman, who is expected to begin on October 20, 2025, as Executive Vice President, Chief Legal Officer, succeeding Mr. Cassidy in leading the company’s legal function.
Sana Biotechnology, Inc. disclosed that Mary Agnes Wilderotter has decided to resign from its Board of Directors, effective August 29, 2025. She is also stepping down as Chairperson of the Nominating and Corporate Governance Committee and as a member of the Audit Committee.
The company states that Ms. Wilderotter’s resignation is not due to any disagreement with Sana on matters related to its operations, policies, or practices. This indicates a governance change but not one tied to a reported dispute over the company’s direction or management.
Sana Biotechnology reported continued development-stage losses and significant balance sheet changes through June 30, 2025. The company recorded a six-month net loss of $143.2 million and a three-month loss of $93.8 million, driven in part by a $44.6 million non-cash impairment of long-lived assets related to its Bothell and Seattle facilities. Total assets fell to $361.6 million from $501.0 million at year-end, and cash and cash equivalents declined to $71.3 million on the balance sheet. Long-term liabilities include $117.1 million of contingent consideration and $8.6 million of success payment liabilities tied to prior acquisitions and license agreements. Management completed an ATM facility and, subsequently, an underwritten offering that together provided additional net proceeds (including $70.0 million from the August offering and $28.6 million raised under the ATM after June 30), and believes available liquidity plus those proceeds will fund planned operations for at least one year. The company reported positive clinical signals for an investigator-sponsored islet transplant (UP421), including C-peptide production and PET-MRI evidence of engraftment, and announced portfolio prioritization toward T1D, B-cell autoimmune diseases, refractory B-cell malignancies, and the fusogen platform.
Sana Biotechnology announced it has issued a press release reporting its financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1 to this Form 8-K. The company states the press release is being furnished and not filed, so it is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless explicitly stated. The 8-K lists Exhibit 99.1 and an Inline XBRL cover page, identifies the registrant as an emerging growth company, and is signed by Acting Chief Financial Officer Susan Wyrick. The company trades on Nasdaq under the ticker SANA.
On 6-Aug-2025 Sana Biotechnology, Inc. (SANA) executed an Underwriting Agreement with Morgan Stanley, Goldman Sachs and BofA to raise capital through a public offering.
- Securities: 20,895,522 common shares at $3.35 and 1,492,537 pre-funded warrants at $3.3499 per underlying share.
- Underwriter purchase price: $3.149 per share and $3.1489 per warrant.
- Greenshoe: 30-day option for up to 3,358,208 additional shares.
- Net proceeds: ≈$70 million to SANA, assuming no option exercise and after fees.
- Closing: expected 8-Aug-2025, subject to customary conditions.
- Warrant terms: $0.0001 exercise price, no expiration, 4.99 % ownership cap (adjustable to ≤19.99 %), cash or cashless exercise, standard anti-dilution and Fundamental Transaction protections.
The raise is being made from shelf registration statement No. 333-277584. All securities are issued by the company, providing immediate liquidity while increasing the share count and potential future dilution.